Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 692

Similar articles for PubMed (Select 18299305)

1.

Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.

Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD.

Pediatrics. 2008 Mar;121(3):e568-73. doi: 10.1542/peds.2007-1405. Epub 2008 Feb 25.

2.

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.

Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, Treanor J, Munoz F, Wolff M, Cho I, Mendelman PM, Cordova J, Belshe RB.

Pediatrics. 2002 Oct;110(4):662-72.

PMID:
12359778
3.

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP.

Pediatrics. 2005 Sep;116(3):e397-407.

4.

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.

Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, Walker R, Hessel C, Cordova J, Mendelman PM.

Pediatr Infect Dis J. 2004 Feb;23(2):138-44.

PMID:
14872180
5.

Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.

Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM; LAIV Study Group.

Pediatrics. 2008 Mar;121(3):508-16. doi: 10.1542/peds.2007-1064.

6.

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.

King JC Jr, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, Newman F, Belshe RB, Kovacs A, Deville JG, Jelonek M; HIV Influenza Study Group.

Pediatr Infect Dis J. 2001 Dec;20(12):1124-31.

PMID:
11740317
7.
8.

Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care.

Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, Skinner J, Saville MK, Gruber WC, Forrest BD; CAIV-T Pediatric Day Care Clinical Trial Network.

Pediatrics. 2006 Dec;118(6):2298-312.

9.

Live attenuated versus inactivated influenza vaccine in infants and young children.

Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative Efficacy Study Group.

N Engl J Med. 2007 Feb 15;356(7):685-96. Erratum in: N Engl J Med. 2007 Mar 22;356(12):1283.

10.

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.

Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD; Pan-Asian CAIV-T Pediatric Efficacy Trial Network.

Pediatr Infect Dis J. 2007 Jul;26(7):619-28.

PMID:
17596805
11.

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.

Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wolff M.

J Pediatr. 2000 Feb;136(2):168-75.

PMID:
10657821
12.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

13.

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):860-9.

PMID:
17006278
14.

Seasonal influenza vaccines.

Fiore AE, Bridges CB, Cox NJ.

Curr Top Microbiol Immunol. 2009;333:43-82. doi: 10.1007/978-3-540-92165-3_3. Review.

PMID:
19768400
15.

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.

Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP.

Pediatrics. 2007 Sep;120(3):e553-64. Epub 2007 Aug 13.

16.

Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.

Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD; D153-P504 LAIV Study Group.

Pediatr Infect Dis J. 2009 May;28(5):365-71. doi: 10.1097/INF.0b013e31819219b8.

PMID:
19395948
17.

Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.

Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD; GRC28 Study Team.

Pediatr Infect Dis J. 2010 Feb;29(2):105-10. doi: 10.1097/INF.0b013e3181b84c34.

PMID:
19934787
18.

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M.

N Engl J Med. 1998 May 14;338(20):1405-12.

19.

Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children.

Piedra PA.

Semin Pediatr Infect Dis. 2002 Apr;13(2):90-6. Review.

PMID:
12122958
20.

Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly.

Treanor JJ, Mattison HR, Dumyati G, Yinnon A, Erb S, O'Brien D, Dolin R, Betts RF.

Ann Intern Med. 1992 Oct 15;117(8):625-33.

PMID:
1530193
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk